On March 29, 2022, the Centers for Disease Control and Prevention (CDC) Nowcast data estimated the proportion of COVID-19 cases caused by the Omicron BA.2 variant to be above 50% in Ohio. Based on this data, Sotrovimab is no longer authorized for use in Ohio. Click here for more information.
The Kettering Health Pharmacy and Therapeutics committee has updated the COVID-19 Outpatient Treatment Algorithm to include bebtelovimab. Bebtelovimab will be provided by the Kettering Health COVID-19 Infusion Center starting Friday April 1, 2022. See attachment for full prescribing, referral process, and paper order form.
Note: Bebtelovimab is still available for Emergency Department administration.
Click here to see attachment for full prescribing, referral process, and paper order form.